

DOCKET NUMBER
PETITION RULE PRM 35-9
(54 FR 38239)

LOCKED
11-11-89

281

'89 NOV 29 P4:25

November 27, 1989

OFFICE OF SECRETARY
DOCKETING & SERVICE
BRANCH

Secretary of the Commission
U.S. Nuclear Regulatory Commission
Docketing and Service Branch, Docket #PRM-35-9
Washington, D.C. 20555

Dear Mr. Secretary:

I am writing to express my strong support for the Petition for Rulemaking filed by the American College of Nuclear Physicians and the Society of Nuclear Medicine. I am a practicing Nuclear Medicine Physician at Mercy-Memorial Medical Center in Benton Harbor, Mi. I am deeply concerned over the revised 10 CFR 35 regulations (effective April, 1987) governing the medical use of byproduct material as they significantly impact my ability to practice high quality Nuclear Medicine and are preventing me from providing optimized care to individual patients.

For example, currently Thallium 201 is not on the package insert for parathyroid imaging. Thallium is the radionuclide of choice when looking for tumors, and is FDA approved. Current NRC restrictions inhibit physicians and their staff from looking into further uses of this radionuclide. Currently, the regulatory provisions in Part 35 (35.100, 35.200, 35.300 and 33.17 (A) (4)) do not allow practices which are legitimate and legal under FDA regulations and State medicine and pharmacy laws. These regulations therefore, inappropriately interfere with the practice of medicine which directly contradicts the NRC's Medical Policy statement against such interference.

The NRC should recognize that the FDA does allow, and often encourages, other clinical uses of approved drugs, and actively discourages the submission of physician-sponsored IND's that describe new indications for approved drugs. In many cases, manufacturers will never go back to the FDA to revise a package insert to include a new indication because it is not required by the FDA and there is simply no economical incentive to do so.

I would like to point out that highly restrictive NRC regulations will only jeopardize public health and safety by: restricting access to appropriate Nuclear Medicine procedures; exposing patient to higher radiation absorbed doses from alternative legal, but non-optimal studies; and exposing hospital personnel to higher radiation absorbed doses because of unwarranted, repetitive procedures. The NRC should not strive to construct proscriptive regulations to cover all aspects of medicine, nor should it attempt to regulate radiopharmaceutical use. Instead, the NRC should rely on the expertise of the FDA State Boards of Pharmacy, State Boards of Medical Quality Assurance, the JCAHO, Radiation Safety Committee, institutional Q/A review procedures, and most importantly, the professional judgement of physicians and pharmacists who have been well trained to administer and prepare these materials.


B912010169 B91127
PDR PRM
35-9 PDR

DS10

I strongly urge the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences or the NCRP, to assess the radiobiological effects of misadministrations from Nuclear Medicine diagnostic and therapeutic studies. I firmly believe that the results of such a study will demonstrate that the NRC's efforts to impose more and more stringent regulations are unnecessary and not cost effective in relation to the extremely low health risks of these studies.

In closing, I strongly urge the NRC to adopt the ACNP/SNM Petition for rulemaking as expeditiously as possible.

Sincerely,



Gene E. Maddock, M.D.
Medical Director
Nuclear Medicine Department
Mercy-Memorial Medical Center

kg
11/27/89